BioSpace News Archive

Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that an editorial written by Maria Sjöstrand and Michel Sadelain of Memorial Sloan Kettering Cancer Center was published 2023 in Haematologica highlighting NXC-201 in the context of the current U.S. Food And Drug Administration (“FDA”) approved BCMA CAR-T Cell therapies.

Artelo Biosciences, Inc. reported financial and operating results for the fiscal year ended December 31, 2022 and provided a business update.

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced its financial results for the full year ended December 31, 2022 and provided a corporate update.

AnHeart Therapeutics (“AnHeart”) announced today updated efficacy and safety data from a regional Phase 2 clinical trial of taletrectinib (TRUST-I) in patients with ROS1-positive non-small cell lung cancer (ROS1+ NSCLC) in an oral presentation at the European Lung Cancer Congress (ELCC) 2023.

ContraFect Corporation(Nasdaq: CFRX) today announces business updates and financial results for the fourth quarter and full year ended December 31, 2022.

Telesis Bio Inc. announced continued expansion of the BioXp® Select Kit product line, releasing two novel kits to enable DNA amplification and scale-up.

Prothena Corporation plc (NASDAQ:PRTA) today announced new preclinical data from its PRX012 program, a potential best-in-class anti-amyloid beta (Aβ) product candidate in development for the treatment of Alzheimer’s disease, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) in Gothenburg, Sweden.

Influenza ( short for influenza) is a common acute respiratory infectious disease caused by influenza virus, common in winter and spring. It is also a highly contagious and rapidly spreading disease. It is mainly transmitted through airborne droplets, person-to-person contact or contact with contaminated objects.

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for the fully automated LUMIPULSE® G Systems.

The Board of Directors of Nordic Nanovector ASA has decided to postpone the upcoming Annual General Meeting, which was originally scheduled for 26 April.